Association Between Patent Ductus Arteriosus and the Development of Treatment-Requiring Retinopathy of Prematurity in Preterm Infants: A Single-Center Cohort Study

<b>Background/Objectives</b>: Retinopathy of prematurity (ROP) is a significant cause of childhood blindness, particularly among preterm infants. Patent ductus arteriosus (PDA) is commonly observed in neonates and may contribute to the development of ROP through increased oxygen delivery to the retina. However, the association between PDA and the severity of ROP remains unclear. This study aims to evaluate the relationship between PDA and the development of treatment-requiring ROP in preterm infants. <b>Methods</b>: A retrospective cohort study was conducted on preterm infants born between 2014 and 2020 at Izmir Private Medical Park Hospital. Infants with a birth weight of less than 2000 g and a gestational age of ≤36 + 6 weeks were included. Data on demographics, prematurity-related complications, PDA status, ROP severity, and treatment requirements were collected. Statistical analysis was performed using univariate and multivariate logistic regression models to identify predictors of ROP. <b>Results</b>: Of 516 infants, 328 did not have PDA, 117 had spontaneous PDA closure, and 71 required PDA treatment. Neonates requiring PDA treatment had significantly lower gestational age and birth weight, as well as longer respiratory support duration. PDA presence was associated with increased ROP incidence in univariate analysis (<i>p</i> < 0.001); however, it was not an independent predictor of treatment-requiring ROP in multivariate models. Significant predictors for treatment-requiring ROP included longer non-invasive ventilation duration (OR = 1.029) and total respiratory support (OR = 1.009). <b>Conclusions</b>: The findings of this study highlight the central role of respiratory morbidity in ROP pathogenesis and suggest that optimal respiratory management may be more critical for ROP prevention than PDA treatment alone.